$KLTO
Stock $klto

$klto Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023069521 Filed on August 21, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$292.2K	$358.0K
YoY Change	62.59%	53.8%
% of Gross Profit
Research & Development		$0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$292.2K	$358.0K
YoY Change	62.59%	53.8%
Operating Profit	-$292.2K	-$358.0K
YoY Change	62.6%	53.8%
Interest Expense	$741.8K	$399.6K
YoY Change	137.61%	172.92%
% of Operating Profit
Other Income/Expense, Net	-$10.60K	-$21.20K
YoY Change	-101.56%	-82.69%
Pretax Income	$439.0K	$20.40K
YoY Change	-45.86%	-109.77%
Income Tax	$148.9K	$173.9K
% Of Pretax Income	33.91%	852.69%
Net Earnings	$290.1K	-$153.5K
YoY Change	-60.32%	-26.47%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.02
Diluted Earnings Per Share	$0.03	-$0.02
COMMON SHARES
Basic Shares Outstanding	8.802M shares	8.802M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.3K	$123.7K
YoY Change	-64.67%	-72.35%
Cash & Equivalents	$146.3K	$123.7K
Short-Term Investments
Other Short-Term Assets	$57.48K	$135.2K
YoY Change	-59.23%	-38.03%
Inventory
Prepaid Expenses	$57.48K	$135.2K
Receivables
Other Receivables
Total Short-Term Assets	$203.8K	$258.9K
YoY Change	-63.29%	-61.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$57.81M	$56.95M
YoY Change	-50.42%	-51.03%
Other Assets
YoY Change
Total Long-Term Assets	$57.81M	$56.95M
YoY Change	-50.42%	-51.03%
TOTAL ASSETS
Total Short-Term Assets	$203.8K	$258.9K
Total Long-Term Assets	$57.81M	$56.95M
Total Assets	$58.02M	$57.21M
YoY Change	-50.48%	-51.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$327.6K	$273.5K
YoY Change	446.07%	811.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.664M	$1.352M
YoY Change	662.12%	1850.48%
LONG-TERM LIABILITIES
Long-Term Debt	$1.140M	$870.0K
YoY Change
Other Long-Term Liabilities	$4.387M	$4.376M
YoY Change	0.98%	-12.87%
Total Long-Term Liabilities	$5.527M	$5.246M
YoY Change	27.22%	4.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.664M	$1.352M
Total Long-Term Liabilities	$5.527M	$5.246M
Total Liabilities	$7.243M	$6.726M
YoY Change	58.73%	32.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.436M	-$6.046M
YoY Change	60.58%	41.25%
Common Stock	$340.00	$340.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.436M	-$6.046M
YoY Change
Total Liabilities & Shareholders Equity	$58.02M	$57.21M
YoY Change	-50.48%	-51.09%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$290.1K	-$153.5K
YoY Change	-60.32%	-26.47%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$123.9K	-$513.5K
YoY Change	272.62%	30.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$121.3K	$63.33M
YoY Change		-154.52%
Cash From Investing Activities	-$121.3K	$63.33M
YoY Change		-154.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	270.6K	-62.81M
YoY Change		-153.69%
NET CHANGE
Cash From Operating Activities	-123.9K	-513.5K
Cash From Investing Activities	-121.3K	63.33M
Cash From Financing Activities	270.6K	-62.81M
Net Change In Cash	25.37K	5.740K
YoY Change	-176.32%	-98.7%
FREE CASH FLOW
Cash From Operating Activities	-$123.9K	-$513.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense		usd
	rwod	Allocation Of Offering Costs To Common Stock Subject To Redemption AllocationOfOfferingCostsToCommonStockSubjectToRedemption		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41340
	dei	Entity Registrant Name EntityRegistrantName	Redwoods Acquisition Corp.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2727441
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1115 Broadway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	12th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10010
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	916-5315
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8801650	shares
CY2023Q2	us-gaap	Cash Cash	123722	usd
CY2022Q4	us-gaap	Cash Cash	340962	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	135196	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	99196	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	258918	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	440158	usd
CY2023Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	56950088	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	117806478	usd
CY2023Q2	us-gaap	Assets Assets	57209006	usd
CY2022Q4	us-gaap	Assets Assets	118246636	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	273522	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	140370	usd
CY2023Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	66000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	122801	usd
CY2023Q2	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	380468	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	243070	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	631696	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1351686	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	506241	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	63600	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	31800	usd
CY2023Q2	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	128162	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	78955	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	870000	usd
CY2023Q2	rwod	Deferred Underwriting Fee Payables DeferredUnderwritingFeePayables	4312500	usd
CY2022Q4	rwod	Deferred Underwriting Fee Payables DeferredUnderwritingFeePayables	4312500	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6725948	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4929496	usd
CY2023Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5396650	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	11500000	shares
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.21
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	56528771	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	117361652	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	340	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	340	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6046053	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4044852	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6045713	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4044512	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57209006	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118246636	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	324051	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	193440	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	617705	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	198450	usd
CY2023Q2	us-gaap	Franchisor Costs FranchisorCosts	33900	usd
CY2022Q2	us-gaap	Franchisor Costs FranchisorCosts	39300	usd
	us-gaap	Franchisor Costs FranchisorCosts	66000	usd
	us-gaap	Franchisor Costs FranchisorCosts	39300	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-357951	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-232740	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-683705	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-237750	usd
CY2023Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	862224	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	146397	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2112292	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	146397	usd
CY2023Q2	rwod	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-462670	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21200	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	122483	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	31800	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	122483	usd
CY2023Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	20403	usd
CY2022Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-208826	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	1396787	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-213836	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	173949	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	429722	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-153546	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-208826	usd
	us-gaap	Net Income Loss NetIncomeLoss	967065	usd
	us-gaap	Net Income Loss NetIncomeLoss	-213836	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4044512	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1322195	usd
CY2023Q1	rwod	Stock Issued During Period Value Exercise Tax Liability StockIssuedDuringPeriodValueExerciseTaxLiability	-631696	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1120611	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4877792	usd
CY2023Q2	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1014375	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-153546	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6045713	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3559	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5010	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16431	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	115000000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	5300000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	100	usd
CY2022Q2	rwod	Stock Issued During Period Value Underwriter Commissions StockIssuedDuringPeriodValueUnderwriterCommissions	-7187500	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-462536	usd
CY2022Q2	rwod	Stock Issued During Period Value Warrant Liabilities StockIssuedDuringPeriodValueWarrantLiabilities	-587717	usd
CY2022Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	96338934	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6901405	usd
CY2022Q2	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	26712471	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-208826	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-4280048	usd
	us-gaap	Net Income Loss NetIncomeLoss	967065	usd
	us-gaap	Net Income Loss NetIncomeLoss	-213836	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	2112292	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	146397	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	31800	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	122483	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	36001	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	218173	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	133152	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	30000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-56801	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	39300	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	137398	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	49207	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-886472	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-386623	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	116150000	usd
	us-gaap	Proceeds From Sale Of Insurance Investments ProceedsFromSaleOfInsuranceInvestments	519232	usd
	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	63169451	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	720000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	62968683	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-116150000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	115000000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5300000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	100	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	870000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	63169451	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	200000	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-8511	usd
	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	2875000	usd
	rwod	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	462536	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-62299451	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116979053	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-217240	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	442430	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	340962	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4952	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123722	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	447382	usd
	rwod	Initial Classification Of Common Stock Subject To Redemption InitialClassificationOfCommonStockSubjectToRedemption	96338934	usd
	rwod	Initial Recognition Of Warrant Liabilities InitialRecognitionOfWarrantLiabilities	587717	usd
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	4312500	usd
	rwod	Allocation Of Offering Costs To Common Stock Subject To Redemption AllocationOfOfferingCostsToCommonStockSubjectToRedemption	6901405	usd
	us-gaap	Stock Issued1 StockIssued1	2336570	usd
	us-gaap	Stock Issued1 StockIssued1	26712471	usd
	rwod	Redeemed Common Stock Payable RedeemedCommonStockPayable	63169451	usd
	rwod	Exercise Taxliability ExerciseTaxliability	631696	usd
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q2	rwod	Total Gross Proceeds TotalGrossProceeds	4775000	usd
	rwod	Additional Public Units AdditionalPublicUnits	1500000	shares
CY2022Q2	rwod	Purchased Public Units PurchasedPublicUnits	1500000	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q2	rwod	Total Gross Proceeds TotalGrossProceeds	525000	usd
CY2023Q2	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	8365339	usd
	rwod	Underwriting Fees UnderwritingFees	2875000	usd
	rwod	Deferred Underwriting Fees DeferredUnderwritingFees	4312500	usd
	rwod	Other Offering Costs OtherOfferingCosts	1177839	usd
CY2022Q2	rwod	Total Amount TotalAmount	116150000	usd
CY2022Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P185D
	rwod	Aggregate Of Shares AggregateOfShares	6103350	shares
	rwod	Redemption Value RedemptionValue	63169451	usd
CY2023Q2	rwod	Redemption Per Share RedemptionPerShare	10.35
	rwod	Initial Threemonth Extension InitialThreemonthExtension	360000	usd
	rwod	Onemonth Extension OnemonthExtension	120000	usd
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.1
	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1	pure
CY2023Q2	rwod	Trust Account Amount TrustAccountAmount	360000	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.1
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	60000000	usd
	rwod	Description Of Contingent Consideration Shares DescriptionOfContingentConsiderationShares	(i) 2,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $12.50 for 10 trading days within a 20-day trading period in the first three years following the closing of the Merger; (ii) 2,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $15.00 for 10 trading days within a 20-day trading period in the first three years following the closing of the Merger; and (iii) 1,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $20.00 for 10 trading days within a 20-day trading period in the first five years following the closing of the Merger
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2875000	shares
	rwod	Founder Shares FounderShares	1375000	shares
	rwod	Description Of Deferred Shares DescriptionOfDeferredShares	(i) 458,333 Deferred Shares upon the Company achieving a closing price equal to or exceeding $12.50 for 10 trading days within a 20-day trading period in the first three years following the closing of the Merger; (ii) 458,333 Deferred Shares upon the Company achieving a closing price equal to or exceeding $15.00 for 10 trading days within a 20-day trading period in the first three years following the closing of the Merger; and (iii) 458,333 Deferred Shares upon the Company achieving a closing price equal to or exceeding $20.00 for 10 trading days within a 20-day trading period in the first five years following the closing of the Merger.
CY2023Q2	us-gaap	Cash Available For Distributions CashAvailableForDistributions	123722	usd
CY2023Q2	rwod	Working Capital Deficit WorkingCapitalDeficit	646300	usd
CY2023Q1	rwod	Sponsor Provided Loan SponsorProvidedLoan	150000	usd
CY2023Q1	rwod	Sponsor Provided Loan SponsorProvidedLoan	360000	usd
CY2023Q2	rwod	Sponsor Provided Loan SponsorProvidedLoan	360000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	631696	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these unaudited condensed consolidated financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </p>
	us-gaap	Dividends Cash DividendsCash	123722	usd
CY2022	us-gaap	Dividends Cash DividendsCash	340962	usd
CY2023Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	8365339	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	8.5252	pure
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3076	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.03	pure
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-153546	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-208826	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	967065	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-213836	usd
CY2023Q2	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-1014375	usd
CY2022Q2	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-26712471	usd
	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-2336570	usd
	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-26712471	usd
CY2023Q2	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	-1167921	usd
CY2022Q2	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	-26921297	usd
	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	-1369505	usd
	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	-26926307	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution and money market funds held in the Trust Account. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	150000	usd
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	360000	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	870000	usd
	us-gaap	Interest Costs Incurred InterestCostsIncurred	60000	usd
	us-gaap	Interest Costs Incurred InterestCostsIncurred	30000	usd
	rwod	Accrued Expenses AccruedExpenses	150000	usd
	us-gaap	Interest Income Securities Us Treasury InterestIncomeSecuritiesUSTreasury	56950088	usd
CY2022	us-gaap	Interest Income Securities Us Treasury InterestIncomeSecuritiesUSTreasury	117806478	usd
	rwod	Accrued Expenses AccruedExpenses	90000	usd
CY2023Q2	rwod	Prospectus To Purchase ProspectusToPurchase	1500000	shares
	us-gaap	Underwriting Expense Ratio UnderwritingExpenseRatio	0.025	pure
	rwod	Generating Gross Proceeds GeneratingGrossProceeds	2875000	usd
	rwod	Deferred Fee DeferredFee	0.0375	pure
CY2023Q2	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	56950088	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	117806478	usd
CY2023Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	1500000	usd
CY2023Q2	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
	us-gaap	Partners Capital Account Units Sold In Public Offering PartnersCapitalAccountUnitsSoldInPublicOffering	11500000	shares
CY2022	rwod	Gross Proceed GrossProceed	115000000	usd
CY2022Q4	rwod	Proceeds Allocated To Public Warrants ProceedsAllocatedToPublicWarrants	-10695000	usd
CY2022Q4	rwod	Proceeds Allocated To Public Rights ProceedsAllocatedToPublicRights	-9430000	usd
CY2022Q4	rwod	Offering Costs Of Public Shares OfferingCostsOfPublicShares	-6901405	usd
CY2022	rwod	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	29388057	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	117361652	usd
	rwod	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	2336570	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-63169451	usd
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	56528771	usd
	rwod	Aggregate Private Units AggregatePrivateUnits	477500	shares
CY2023Q2	rwod	Sale Of Stock Price Per Shares SaleOfStockPricePerShares	10
	rwod	Aggregate Purchase Price AggregatePurchasePrice	4775000	usd
	rwod	Additional Aggregates Private Units AdditionalAggregatesPrivateUnits	52500	shares
	us-gaap	Sale Leaseback Transaction Gross Proceeds Financing Activities SaleLeasebackTransactionGrossProceedsFinancingActivities	525000	usd
CY2023Q2	us-gaap	Purchase Options Land PurchaseOptionsLand	100	usd
	rwod	Unit Purchase Option UnitPurchaseOption	345000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.5
	rwod	Aggregate Exercise Price AggregateExercisePrice	3967500	usd
	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P5Y
	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	100	usd
	rwod	Right Of First Refusal Description RightOfFirstRefusalDescription	The Company has granted Chardan a right of first refusal, for a period of 18 months after the date of the consummation of a Business Combination, to act as a book-running manager or placement agent, with at least 30% of the economics, for any and all future public and private equity, equity linked and debt offerings of the Company or any of its successors or subsidiaries.
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2023Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	5396650	shares
	rwod	Market Price Percentage MarketPricePercentage	1.15	pure
CY2023Q2	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	16.5
	rwod	Market Valuein Percentage MarketValueinPercentage	1.65	pure
CY2023Q2	rwod	Price Per Warrant PricePerWarrant	0.01
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	16.5
CY2023Q2	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	63600	usd
CY2022Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	31800	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	31800	usd
	rwod	Change In Fair Value ChangeInFairValue	31800	usd
CY2023Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	63600	usd
CY2022Q2	rwod	Fair Value Of Private Warrants FairValueOfPrivateWarrants	587717	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2023Q2	rwod	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Underlying Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsUnderlyingSharePrice	10.46
CY2022Q2	rwod	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Underlying Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsUnderlyingSharePrice	8.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0636	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2562	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0413	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0242	pure
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable		usd
CY2023Q2	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.41
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
	us-gaap	Proceeds From Sale Of Insurance Investments ProceedsFromSaleOfInsuranceInvestments		usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement		usd
	rwod	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts		usd
	rwod	Initial Classification Of Common Stock Subject To Redemption InitialClassificationOfCommonStockSubjectToRedemption		usd
	rwod	Initial Recognition Of Warrant Liabilities InitialRecognitionOfWarrantLiabilities		usd
	rwod	Redeemed Common Stock Payable RedeemedCommonStockPayable		usd
	rwod	Exercise Taxliability ExerciseTaxliability		usd
CY2023Q2	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001907223

Files In Submission

Name	View Source	Status
rwod-20230630_cal.xml	Edgar Link	unprocessable
0001213900-23-069521-index-headers.html	Edgar Link	pending
0001213900-23-069521-index.html	Edgar Link	pending
0001213900-23-069521.txt	Edgar Link	pending
0001213900-23-069521-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_redwoods.htm	Edgar Link	pending
f10q0623ex31-2_redwoods.htm	Edgar Link	pending
f10q0623ex32-1_redwoods.htm	Edgar Link	pending
f10q0623ex32-2_redwoods.htm	Edgar Link	pending
f10q0623_redwoodsacq.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rwod-20230630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_redwoodsacq_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
rwod-20230630_pre.xml	Edgar Link	unprocessable
rwod-20230630_lab.xml	Edgar Link	unprocessable
rwod-20230630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KLTO
Stock $klto

2023 Q3 Form 10-Q Financial Statement

#000121390023069521 Filed on August 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KLTO Stock $klto

2023 Q3 Form 10-Q Financial Statement

#000121390023069521 Filed on August 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KLTO
Stock $klto